🇺🇸 FDA
Pipeline program

VEGF inhibitor PTC299

CDR0000680634

Phase 1 small_molecule completed

Quick answer

VEGF inhibitor PTC299 for Brain and Central Nervous System Tumors is a Phase 1 program (small_molecule) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PTC THERAPEUTICS, INC.
Indication
Brain and Central Nervous System Tumors
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials